The laboratory diagnosis of Lyme disease is based upon the detection of antibodies generated against Borrelia burgdorferi using a two-tier assay, typically consisting of an enzyme-linked immunosorbent assay (ELISA), followed by a Western blot. This system, put into place to address the nonspecificity associated with standalone first-tier assays, is insensitive for diagnosing early infection, when most people seek care. The use of bacterial lysates or whole-protein antigens as first-tier assay targets contributes to nonspecificity due, in part, to the presence of cross-reactive epitopes that are also found in other bacteria. This precludes their use as sensitive standalone assays. The use of peptides containing linear epitopes that are highly specific for B. burgdorferi offers a method for reducing this cross-reactivity. In the present study, we mapped the linear epitopes of the prominently expressed Borrelia adhesins decorin binding protein A (DbpA) and DbpB. We identified several epitopes in each protein that were highly conserved among North American strains of B. burgdorferi, and we screened peptides containing specific epitopes using serum panels from early and late Lyme disease patients. The individual peptides primarily detected IgM but not IgG, while the proteins efficiently detected both IgM and IgG. While no individual peptide demonstrated better utility for antibody detection than its respective whole protein, an assay containing a combination of a DbpA and a DbpB peptide adequately detected both IgM and IgG, accurately identifying 87.5% (84/96) of the early Lyme disease patients and 80.0% (16/20) of the late Lyme disease patients.
L
yme disease is a tick-transmitted infectious disease that can affect multiple organ systems, including the skin, joints, and the cardiovascular and nervous systems (1, 2) . In North America, it is caused by the bacterium Borrelia burgdorferi sensu stricto, while in Europe and Asia, Lyme disease is caused by multiple Borrelia genospecies (principally B. burgdorferi, B. garinii, and B. afzelii) (1, 2) . The only distinguishing feature of Lyme disease is a characteristic skin lesion, erythema migrans (EM), which occurs in the majority of early Lyme disease patients (1, 2) . In areas where the disease is endemic, the presence of EM in an appropriate clinical setting is sufficient for Lyme disease diagnosis (1) (2) (3) (4) . However, EM does not develop in as many as 20% of early Lyme disease patients and, although EM is diagnostic, atypical EM is relatively common. Less than 50% of EM have a typical bull's-eye appearance. This can result in confusion, leading to delayed diagnosis or misdiagnosis (3, 4) . Early antibiotic treatment is highly effective and critical for preventing disease progression, which can result in permanent damage to the nervous and musculoskeletal systems (1, 2) .
In the absence of EM, the laboratory diagnosis of Lyme disease is primarily dependent on the detection of antibodies against B. burgdorferi using a two-tier detection paradigm (5) . This paradigm, usually a first-tier enzyme-linked immunosorbent assay (ELISA) that if positive or equivocal is followed by a second-tier Western blot, was put into place in the mid-1990s to help address the lack of specificity found in the first-tier assays (5) . Nonspecificity associated with the first-tier assays is attributable, at least in part, to cross-reactive antigens, such as the flagellin and heat shock proteins, which contain regions of high homology to proteins expressed in other bacteria (6, 7) . The inclusion of the second-tier Western blot improved specificity, but as it is a less sensitive assay than the first-tier ELISA, it ultimately reduced the sensitivity of the whole two-tier paradigm. While two-tier testing has been useful, it lacks sufficient sensitivity at the time many patients with early Lyme disease usually seek initial medical care, failing to detect diagnostic levels of antibodies approximately 50% of the time (6, (8) (9) (10) (11) (12) (13) . If the specificity of the first-tier assays were improved, second-tier assays could be eliminated, increasing the sensitivity of serodiagnostics.
One method for improving the specificity of first-tier assays, and therefore eliminating the need for less sensitive second-tier assays, is through the use of synthetic peptides that contain epitopes unique to prominently expressed B. burgdorferi antigens as assay targets (9, 13, (13) (14) (15) (16) (17) . ELISAs utilizing synthetic peptides (PepC10 and C6) have demonstrated improved sensitivity for the serological diagnosis of acute Lyme disease compared to that with conventional two-tier testing (7, 13, 15, 18, 19) . Improved specificity provided by synthetic peptides may be, in part, due to the elimination of conserved structural motifs and/or linear amino acid sequences found in similar proteins expressed by other bacterial species, although this has never been directly proven. The current single-peptide assays have limitations, however. Seroreactivity in a peptide-based assay is entirely sequence specific (10) , and the IR6 sequence of VlsE, from which C6 is derived, has been found to be more variable among the different B. burgdorferi genospecies than was first thought (7, 12, 13, 15, (18) (19) (20) . Furthermore, C6 binds IgM poorly, reducing its value in the diagnosis of early Lyme disease (7, 12, 13, 15, 18, 20) . Regardless, the successes of the C6 assay warrant further development of peptide-based technologies. The suggested limitations of the C6 assay can be overcome through the use of a peptide-based assay containing multiple-peptide antigens.
Decorin binding proteins (Dbp) A and B are surface-exposed outer membrane lipoproteins that mediate the attachment of Borrelia to the extracellular matrix and connective tissue in host animals and humans (18, (21) (22) (23) (24) (25) (26) (27) (28) . DbpA was evaluated as an antigen target for the serodiagnosis of Borrelia-infected individuals in Europe and Asia. However, the efficacy of DbpA as an antigen target was limited because of its considerable sequence variability found among the different pathogenic genospecies of Borrelia (B. burgdorferi, B. garinii, and B. afzelii) found in Eurasia (18, 21, 25, 26, 29, 30) . This is similar in many ways to the variability observed in the OspC protein. In North America, where Lyme disease is solely attributed to infection with B. burgdorferi, the utility of DbpA (and DbpB) as a target antigen for serodiagnosis has yet to be properly evaluated.
Previously, we performed linear epitope mapping of the OspC and OppA antigens of B. burgdorferi, identifying conserved peptides that functioned as effective targets for the serodiagnosis of early Lyme disease (16, 17) . In the present study, we mapped the linear epitopes of the antigens DbpA and DbpB and generated synthetic peptides containing the identified epitopes. These peptides are capable of identifying patients with early Lyme disease that may serve as potential targets within a multipeptide serological diagnostic assay.
MATERIALS AND METHODS
Patient samples. The Lyme disease patient samples were collected under informed consent, with institutional review board (IRB) approval from the respective institutions. One hundred four serum samples were collected from patients diagnosed with Lyme disease upon initial presentation with an erythema migrans lesion (EM ϩ ) at Stony Brook University, Stony Brook, NY (n ϭ 22), at Westchester Medical Center, Valhalla, NY (n ϭ 32), or at Gundersen-Lutheran Medical Center, La Crosse, WI (n ϭ 50). The 50 samples from Gundersen-Lutheran Medical Center were confirmed to be positive by a clinician-documented EM lesion of Ͼ4 cm, appropriate epidemiologic history (e.g., tick bite or exposure), and seropositivity by whole-cell ELISA (Vidas; bioMéri-eux, Durham, NC). The clinical laboratory results for the other Lyme disease patients were not made available to us. In addition, 20 late Lyme disease samples were collected from patients with Lyme arthritis (LA) (n ϭ 20) who had one or more episodes of swollen joints, appropriate epidemiologic history, and positive reactivity by whole-cell ELISA (Vidas) at the Gundersen-Lutheran Medical Center. Lyme disease is highly endemic in all three regions where samples were collected. The serum samples from healthy individuals were collected in New Mexico (n ϭ 64) and California (n ϭ 38) and were purchased from Creative Testing Solutions (Tempe, AZ) and Bioreclamation LLC (Westbury, NY), respectively. The serum samples collected from patients with rheumatoid arthritis (RA) (n ϭ 48) or who had a positive rapid plasma reagin (RPR ϩ ) test result (n ϭ 39) were purchased from Bioreclamation LLC. The RPR test is a first-tier test for the laboratory diagnosis of syphilis, which is caused by the spirochete Treponema pallidum. Of the 39 RPR ϩ serum samples used in this study, 38 tested positive or equivocal for antibodies against T. pallidum by ELISA (Abnova, Walnut, CA). The RPR ϩ and RA control sera were collected in areas that have Lyme disease (i.e., the northeastern United States).
Epitope mapping and peptides. Epitope mapping of full-length DbpA from B. burgdorferi strain B31 (GenBank accession no. AAC66250) was performed by ProImmune, Inc. (Oxford, United Kingdom) using their proprietary ProArray Ultra peptide microarray technology, as described previously (16) . The epitope mapping of DbpB was performed by Arrayit Corp. (Sunnyvale, CA). Briefly, an overlapping peptide library consisting of 20-amino-acid (aa)-long peptides overlapping by 15 aa (offset by 5 aa) was generated using the sequence for DbpB from B. burgdorferi B31 (GenBank accession no. AAC66244). The sequence submitted for mapping lacked the first 8 aa. The library was exposed to 8 patient serum samples containing antibodies against B. burgdorferi proteins, as determined by commercial Lyme immunostrips (Viramed Biotech AG, Planegg, Germany). Four serum samples were from acute-phase (firstvisit) patients, and four serum samples were from convalescent-phase (30-day return visit) patients diagnosed at the seasonal Lyme disease clinic at New York Medical College. The acute-and convalescent-phase sera were not paired, as they were from different patients. IgM and IgG binding were independently evaluated, and the data were reported in terms of fluorescence binding intensity. After analyzing the epitope mapping data, we designed a series of peptides containing selected epitope sequences. These peptides were produced by LifeTein LLC (South Plainfield, NJ). Homologous sequences were identified using the protein BLAST algorithm on the NCBI website ( Fig. 1 and 2 and Tables 1 and 2 ). Sequence alignments were constructed for full-length DbpA and DbpB using CLC Workbench (CLC bio, Cambridge, MA); only the regions of the alignments corresponding to the epitopes of interest are displayed ( Fig. 1 and 2) .
ELISA. Immunoreactivity to the peptide antigens was confirmed by ELISA, as previously described (16) . Briefly, 96-well plates were coated with 10 g/ml single peptides, 5 g/ml each peptide when coating with two peptides (for a final concentration of 10 g/ml), or 0.5 g/ml recombinant protein. The sera were added at a 1:100 dilution. Antibody binding was detected by adding a 1:8,000 dilution of IgM (-chain specific) or a 1:5,000 dilution of horseradish peroxidase (HRP)-labeled goat anti-human IgG (␥-chain specific) (SouthernBiotech, Birmingham, AL). The data are presented as the absorbance at 450 nm.
Data analysis. Statistical analysis was performed using Prism 6.0 (GraphPad, La Jolla, CA). Statistical differences in the mean absorbances of antibody binding to peptide or protein were determined using a Kruskal-Wallis nonparametric test, followed by a Dunn's multiple-comparison test. The sensitivity and specificity of each peptide were calculated via receiver operating characteristic (ROC) analysis comparing IgM and IgG binding in Lyme patient sera with negative controls. The cutoff value used for comparing sensitivity and specificity was 3 standard deviations (SD) from the mean of the healthy controls. The statistical analysis of the categorical data presented in the tables and text was performed using a chi-square analysis.
RESULTS
The linear epitope mapping of DbpA revealed two regions that bound antibody in all 8 serum samples, DbpA at positions 6 to 30 [DbpA (6 -30) ] in the N-terminal region and DbpA(76 -90) in the middle of the protein (Fig. 1) . The region corresponding to DbpA(6 -30) contained three overlapping peptides in the peptide library (Fig. 1) ; however, the peptide region DbpA (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) was not properly synthesized due to the chemical properties of that particular amino acid sequence. As a result, 3 peptides were generated from that region for further analysis, DbpA (6 -20) , DbpA (16 -30) , and DbpA(6 -30), which contains the interceding region that was not produced independently; in addition, a single peptide was generated from the sequence DbpA(76 -90) (Fig. 1) . The linear epitope mapping results were more ambiguous for DbpB; each patient serum sample bound to multiple different sequences in the peptide library. Unlike the epitope mapping performed for DbpA, which measured total antibody binding, the method for performing the epitope mapping of DbpB differentiated between IgM and IgG binding. Three peptides were chosen for further analysis: DbpB(18 -37) was bound by IgG in 100% of the samples but IgM in only 25%, DbpB(148 -167) was bound by both IgM and IgG in 100% of the samples, and DbpB(38 -67), which comprised two overlapping peptides, DbpB(38 -57), bound by IgM in 100% of the samples, and DbpB(48 -67), bound by IgG in 100% of the samples (Fig. 2) . These three peptides contained the only epitopes that were recognized by IgM, IgG, or both IgM and IgG in all eight serum samples. Numerous other DbpB peptides that were bound by antibody in some, but not all, patient serum samples were excluded from further analysis.
Short-peptide-based diagnostics are dependent upon antibody recognition of linear amino acid sequences within a protein. Therefore, the efficacy of a peptide-based diagnostic assay is contingent upon the target sequence being highly conserved among the disease-causing bacteria. Variations of the sequence might give rise to antibodies that do not bind the assay target, resulting in false negatives. DbpA has been described as having a high degree of sequence variability among the different species of diseasecausing Borrelia, while DbpB is believed to be less variable (18, 21, 25, 26, 29, 30) . In accordance with this, we found a high degree of variability in the epitope sequences from both DbpA and DbpB among the different strains of Borrelia: the sequence homologies varied from 26.7% to 100.0% for the various epitopes identified (Tables 1 and 2 ). However, deviations from B. burgdorferi B31 were principally observed in the European isolates of B. burgdorferi, B. garinii, and B. afzelii. Within strains of B. burgdorferi isolated in the United States, there was a high degree of sequence conservation (93.3% to 100%). The notable two exceptions were an insertion in the sequence of DbpA(76 -90) in B. burgdorferi strain CA-11.2A (Ͻ50% homology), and a number of amino acid substitutions in the sequences of DbpA (6 -20) , DbpA (16 -30) , and DbpA (6 -30) in B. burgdorferi strain N40 (60% homology for each) (Fig. 1) . Clearly, while not an exhaustive list of the B. burgdorferi isolates, these data suggest that limited sequence variability exists in DbpA and DbpB sequences among the strains isolated in the United States. This increases the likelihood that peptides containing the linear epitopes identified here might be a useful addition to serologic assays, especially in North America.
The efficacies of the DbpA and DbpB peptides as antigen targets were assessed by ELISA. The peptides were incubated with panels of serum from patients with erythema migrans (EM ϩ ) (early Lyme disease), Lyme arthritis (LA) (late Lyme disease), rheumatoid arthritis (RA), syphilis (RPR ϩ ), and healthy individuals, and these were compared to binding with their respective "parent" recombinant Dbp (rDbp). The early Lyme disease serum samples were collected from patients upon initial clinical presentation with an erythema migrans skin lesion (EM ϩ ) in regions where the disease is endemic. The RPR ϩ sera were used as negative controls for potential cross-reactive antibodies generated against a related spirochete, T. pallidum. The RA sera were used as a negative control for chronic inflammation marked by high antibody levels and joint damage. The peptide binding efficacies of both IgM and IgG were independently evaluated in the patient sera, because EM can develop earlier than the production of a detectable IgG response. Individual cutoffs were established for each peptide by determining the mean absorbance of IgM and IgG binding in healthy control sera and calculating values for 3ϫ the standard deviation (positive cutoff) and 2ϫ the standard deviation (equivocal cutoff). Any negative disease or healthy serum control that was positive or equivocal for binding to peptides or recombinant protein was assessed for positivity for Lyme disease using commercially available Lyme immunostrips. Only those control sera that were negative for Lyme disease via these strips were included in the analysis. DbpA (6 -20) , DbpA(6 -30), DbpA (16 -30) , and DbpA(76 -90) were evaluated as targets for the detection of IgM or IgG in EM ϩ patient sera in an ELISA format ( Fig. 3 and Table 3 ; see also Table S1 in the supplemental material). DbpA (16 -30) was the most effective peptide target for the detection of IgM, positively identifying 37.5% (39/104) of the EM ϩ patient serum samples ( Fig. 3a and (Fig. 3a and Table 3 ). The positive binding of IgG to all four peptides was poor, as IgG binding was detected in Ͻ12.5% of the early Lyme disease samples (Fig. 3b and Table 3; see also Table  S1 ). In contrast, IgG binding to the whole DbpA protein was significantly higher (56/103 [54.3%]; P Ͻ 0.0001 for protein versus all peptides), indicating that DbpA-specific IgG was present in the early Lyme disease patient sera. When the total number of samples positive for either IgM or IgG was considered (as some samples were positive for one or the other but not both), DbpA (16 -30) was the most effective peptide target, positively detecting antibodies in 41.3% (43/104) of the EM ϩ early Lyme disease patient sera; however, this remained significantly lower than the number of positive samples identified by rDbpA (73/103 [70.8%]; P Ͻ 0.0001) ( Table 3) .
Three DbpB peptides were identified by epitope mapping: Dbp(18 -37), DbpB(38 -67), and DbpB(148 -167). Of these, DbpB(38 -67) was the most effective peptide for detecting both IgM and IgG in EM ϩ patient serum samples (Fig. 4 and Table 3 ; see also Tables S1 and S2 in the supplemental material). The binding of IgM to DbpB(38 -67) was similar to that of the whole rDbpB protein, at 41.7% (43/103) versus 37.9% (39/103), respectively (Table 3 ). Both were significantly higher than that for DbpB (18 - Fig. 4a and Table 3 versus Table S1 ]. In contrast, the positive binding of IgG to all three peptides was significantly lower than that of rDbpB [P Ͻ 0.01 for DbpB(18 -37) (22/ 103 {21.1%}), DbpB(38 -67) (24/104 {23.1%}), and DbpB(148 -167) (13/104 {12.5%}) versus rDbpB (54/104 {51.9%})] (Fig. 4b and Table 3; see also Table S1 ). Regardless, the positive binding of IgG to the DbpB peptides was generally higher than that of IgG binding to the DbpA peptides, though not significantly (Table 3 ; see other was different for each peptide (Fig. 4 and Table 3; see also  Table S2 ). On the other hand, rDbpA and rDbpB were positively detected by antibody (either IgM or IgG) in 95% (19/20) of the late Lyme disease samples; the same patient sample was negative for both proteins (Fig. 3 and 4 and Table 3 ).
We next assessed the efficacy of a multipeptide diagnostic assay using Dbp peptides by combining a single DbpA peptide, DbpA (16 -30) , with a single DbpB peptide, DbpB(38 -67). These two peptides were selected because each was the most effective target for the positive detection of total antibody (IgM or IgG) in EM ϩ serum for their respective proteins (Table 3) . Ninety-six of the initial 104 EM ϩ early Lyme disease patient serum samples were still in sufficient quantity for the multipeptide analysis. We detected positive IgM binding in 77.1% (74/96) and positive IgG binding in 47.9% (46/96) of the early Lyme disease patient serum samples following coincubation with DbpA (16 -30) plus DbpB(38 -67) (Fig. 5 and Table 4 ). In total, 87.5% (84/96) of the early Lyme serum samples were positive for either IgM or IgG, with 6.25% (6/96) being equivocal and 6.25% (6/96) being negative, which was significantly higher than the rate of detection of either DbpA (16 -30) or DbpB(38 -67) alone (P Ͻ 0.001, Table 4  versus Table 3 ). A similar increase was observed in the abilities of the two peptides to detect late Lyme disease, as 80% (16/20) of the serum samples were positive for antibody binding (either IgM or IgG), with 10% (2/20) being equivocal and 10% (2/20) being negative ( Fig. 5 and Table 4 ). In contrast, combining the recombinant proteins into a single assay had a detrimental effect on antigen binding, reducing the number of both early and late Lyme disease (16 -30) plus DbpB(38 -67) (left panels) and rDbpA plus rDbpB (right panels) in serum samples from patients with early Lyme disease (EM, erythema migrans) (peptides, n ϭ 96; proteins, n ϭ 95), late Lyme disease (LA, Lyme arthritis) (n ϭ 20), healthy controls (normal) (n ϭ 102), rheumatoid arthritis (RA) (peptides, n ϭ 48; proteins, n ϭ 47), or syphilis (RPR ϩ ) (n ϭ 39). The dashed line represents the cutoff for positive binding, 3 SD from the mean (horizontal solid bar) of the healthy controls. The dotted line represents the cutoff for equivocal binding, 2 SD from the mean of healthy controls. **, P Ͻ 0.01; ***, P Ͻ 0.001. (Table 4 versus Tables 1 and 2 ). These data demonstrate that multiple peptides from different antigens, when used in combination, can increase the sensitivity of detection compared to that for individual peptides.
To assess the efficacy of laboratory testing using peptide antigen targets in direct comparison to that of a first-tier whole-cell ELISA, we reanalyzed the data, assessing the binding of either IgM or IgG to peptides and recombinant proteins in the 50 samples known to be positive by whole-cell ELISA (see Table S3 in the supplemental material). DbpA (6 -20) The specificity of the antibody response to Dbp peptides and proteins was determined by assessing IgM and IgG binding in healthy control, RA, and RPR ϩ sera. Minimal antibody binding to peptides was observed in all the control sera. For all peptides, unequivocally positive IgM binding was detected in Յ2 healthy control, RA, or RPR ϩ sera (Table 3; see also Table S1 in the supplemental material). A similar result was observed for IgG binding, with the exceptions of IgG binding to DbpA (6 -30) , which was observed in 4 healthy control samples, and DbpB(148 -167), which was observed in 3 RA samples (Table 3; see also Table S1 ). The binding of IgM and IgG to rDbpA and rDbpB was comparable to that of their respective peptides ( Table 3 ). The binding of IgG to rDbpB was observed in 3 RA and 4 RPR ϩ serum samples but was not significantly different compared to that of the DbpB peptides (Table 3 , P ϭ NS). Combining two peptides, DbpA (16 -30) and DbpB(38 -67), was not associated with a significant increase in the detection of IgM and IgG in negative-control serum compared to individual peptide binding (Table 4) . IgM binding to DbpA (16 -30) plus DbpB(38 -67) was detected in Յ2 samples, and IgG binding was detected in Յ3 healthy control, RA, and RPR ϩ control samples. The sensitivity and specificity of IgM and IgG binding to each peptide and protein were calculated by ROC analysis, using a cutoff of 3 SD from the mean absorbance of the healthy control samples, comparing antibody binding in Lyme disease sera to that of all negative-control sera; these data are presented in Table S4 in the supplemental material. All antigens demonstrated a specificity of Ͼ95%.
DISCUSSION
DbpA and DbpB are two prominent surface-exposed adhesins expressed by B. burgdorferi during the course of human disease. While not expressed in the unfed tick, DbpA (and presumably DbpB, though this has not been directly demonstrated, to our knowledge) are quickly upregulated; it is not clear at the current time if this happens in the tick during feeding or after entry into the host. The placement of DbpA and DbpB in the outer membrane of B. burgdorferi suggests prominent exposure of these proteins to the host immune system. Indeed, in a European study of children with Lyme arthritis, seropositivity to DbpA was present in almost every patient, while antibodies to DbpB were detected in most (10) . In concurrence with this, we identified four peptides from DbpA and three from DbpB that bound to antibodies in 100% of the patient serum samples used for epitope mapping, suggesting that the proteins are highly immunogenic. No differences were observed between the acute-and convalescent-phase sera used for mapping; however, all of the sera used for epitope mapping contained high levels of antibody, which might mask potential differences.
In this exploratory study, individual DbpA and DbpB peptides proved to be less robust antigens than their respective proteins. IgM binding of peptides was more efficient than IgG binding, which is curious because IgM and IgG both bound to whole recombinant proteins with relative equivalency. We observed a similar result in a previous study, in which the OspC1 peptide also bound IgG with less efficiency than it bound IgM. The lack of IgG recognition cannot be explained simply by diminished IgG responses in early disease, as IgG recognition of peptides is also absent in late Lyme disease sera, which should contain an almost entirely IgG response with very little IgM (as observed in IgM and IgG binding to the recombinant proteins). It is possible that the IgG response is primarily directed against conformational epitopes rather than linear ones and that the response to most linear epitopes is not perpetuated following class switching and affinity maturation of B cells. In opposition to this, however, is the well-characterized antibody binding pattern of the C6 peptide derived from VlsE, another peptide antigen that contains at least one linear epitope. C6 is very effective at binding to IgG and less effective at binding IgM (7, 13, 15) , although C6 might be the exception rather than the rule. A third possibility, which is supported by our multipeptide ELISA data (Fig. 5) , is that the level of IgG targeted against our linear epitopes is so low that it is virtually undetectable by ELISA when using single-epitope antigens. This may not be true when using more sensitive methods, such as flow cytometry or Luminex.
When we combined the most effective peptide from DbpA [DbpA (16 -30) ] and the most effective peptide from DbpB [DbpB(38 -67)], we observed a significant increase in the rate of detection in early Lyme disease compared to that with single peptides, increasing from 41.3% and 48.1%, respectively, to 87.5% [P Ͻ 0.001, DbpA (16 -30) with DbpB(38 -67) versus either DbpA (16 -30) or DbpB(38 -67) alone]. Unsurprisingly, combining the peptides resulted in a substantial increase in the individual absorbance values of IgM and IgG binding compared to the values obtained for the single peptides in each early Lyme disease serum sample, elevating them to a detectable level for the majority of the Lyme disease (both early and late) patient samples. In contrast, mixing the recombinant proteins had an unexpected detrimental effect on antibody binding. Far fewer serum samples demonstrated positive binding to a mixture of rDbpA and rDbpB than to either protein individually. It is not clear why this occurred. Though we are unaware of any studies that demonstrate an interaction between DbpA and DbpB, it is possible that the recombinant forms of these two proteins associated when mixed together in solution, shielding epitopes from antibody recognition. The mixing of either peptides or proteins did not result in a significant increase in IgM or IgG binding in the negative-control sera for the two-peptide assay compared to that for the single peptides, although an undesirable rate of antibody binding was observed for both the single and double peptides. These samples were found to be negative for anti-Borrelia antibodies by commercially available Lyme immunostrip analysis (data not shown). The negative-control antibody binding might be the result of cross-reactive antibodies generated against similar antigens or the result of nonspecific interactions with the assay well, blocking reagent, or even the peptides themselves. With the exception of two healthy and one RA control serum sample, different negative-control serum samples were false positive for the DbpA and DbpB peptides. However, if a control serum sample was false positive for one DbpA peptide, it tended to be false positive for all DbpA peptides; the same was true for the DbpB peptides. This increases the likelihood that false-positive reactions were due to nonspecificity rather than cross-reactivity. Experiments are under way to determine if the assay conditions or peptides can be altered to reduce the overall level of nonspecific binding.
One of the principal concerns with peptide-based assays is the identification of highly conserved regions. Variations in the amino acid sequences of a linear epitope can have a significant impact on its utility as an assay target. For example, infection with a bacterium that displayed a variant epitope might result in the generation of antibodies with lower affinities to the assay target sequence that, at the worst, might result in false-negative diagnoses. Significantly, unlike European strains (30) , all but two of the DbpA sequences of the U.S. isolates were identical or highly similar to the sequence derived from B31 used for epitope mapping (Fig. 1) . DbpB sequence variability seemed to be delineated more along species lines (B. burgdorferi versus B. garinii versus B. afzelii), and B. burgdorferi is solely responsible for Lyme disease in the United States (Fig. 2) . These results suggest that Dbp peptides may have utility as diagnostic targets in the United States, but in Europe, multiple different peptides representing each distinct Dbp sequence are likely necessary in order to address the natural sequence variability. In conclusion, we have identified two Dbp peptides, DbpA (16 -30) and DbpB(38 -67), which when used in combination demonstrated efficacy at identifying North American patients with either early or late Lyme disease. Once an array of epitopes from different antigens has been identified and tentative peptide mixtures have been generated, a carefully designed prospective study will be carried out to test the efficacy of these peptides as a component of a multipeptide assay.
